⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

Delcath Systems (United States)

h-index: 3
Total citations: 44
Total papers: 12

Homepage: http://delcath.com/

Recent papers from Delcath Systems (United States)

Phase 1b/2 trial of melphalan-percutaneous hepatic perfusion (PHP) therapy and nivolumab/relatlimab in patients with metastatic melanoma and liver metastasis.Journal of Clinical Oncology · 2026
Phase 2 sequential treatment of percutaneous hepatic perfusion with melphalan/hepatic delivery system followed by tebentafusp in the treatment of metastatic uveal melanoma.Journal of Clinical Oncology · 2026
574eP Safety and feasibility of percutaneous hepatic perfusion with melphalan in patients with liver-dominant metastatic breast cancerESMO Open · 2026
An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal MelanomaAnnals of Surgical Oncology · 2025
Melphalan/hepatic delivery system versus best available care in patients with unresectable metastatic uveal melanoma: Randomized FOCUS trial results.Journal of Clinical Oncology · 2024
Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 StudyAnnals of Surgical Oncology · 2024
Evaluation of Delcath Systems’ Generation 2 (GEN 2) Melphalan Hemofiltration System in a Porcine Model of Percutaneous Hepatic PerfusionCardioVascular and Interventional Radiology · 2014